Association between immune system parameter and clinical characteristics among patients with solid cancer

  • Rahmat Cahyanur Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia
  • Alvina Widhani Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia
  • Nico Iswanto Pantoro Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia
  • Annisa Tsana Madadika Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia
DOI: https://doi.org/10.13181/mji.oa.247272
Keywords: CD4 lymphocyte count, malignancy
Abstract viewed: 61 times
PDF downloaded: 20 times
HTML downloaded: 5 times
EPUB downloaded: 5 times

Abstract

BACKGROUND Lymphopenia has been reported to be a major predictor of chemotherapy-related toxicity. This study aimed to investigate the correlation between neutrophils, lymphocytes, CD4, and CD8 in solid cancer patients and cancer clinical characteristics.

METHODS This was a cross-sectional study of patients who will undergo chemotherapy at the Hematology and Medical Oncology Clinic, Cipto Mangunkusumo Hospital, from June to September 2023. Clinical characteristics, CD4 and CD8 levels, and neutrophil and lymphocyte counts were assessed at the first visit. A comparative test was carried out on the patients’ average CD4, CD8, neutrophil, and lymphocyte counts.

RESULTS Types of cancer were associated with CD4 levels. Patients with head and neck cancer had lower CD4 levels (411.3 [119.3–1,427.5] cells/mm³) compared with colorectal (514.7 [129.2–861.3] cells/mm³), breast and gynecological (567.5 [180.1–939 cells/mm³), and other cancers (681.4 [175.1–2,056.9] cells/mm³), with p = 0.009. Patients aged ≥40 years had higher CD8 levels than those aged <40 years (376.4 [142.8–1,293.1] cells/mm³ versus 565.3 [185.9–1,944] cells/mm³, p = 0.01). Additionally, lymphocyte count was associated with cancer type, with the lowest number in head and neck cancer (1,380 [280–2,660] μl, p = 0.044).

CONCLUSIONS CD4 levels and lymphocyte counts were associated with the cancer type, whereas CD8 levels were influenced by age.

Downloads

Download data is not yet available.

References

  1. Nicholson LB. The immune system. Essays Biochem. 2016;60(3):275−301. https://doi.org/10.1042/EBC20160017

  2. Ostroumov D, Fekete-Drimusz N, Saborowski M, Kühnel F, Woller N. CD4 and CD8 T lymphocyte interplay in controlling tumor growth. Cell Mol Life Sci. 2018;75(4):689−713. https://doi.org/10.1007/s00018-017-2686-7

  3. Mittrücker HW, Visekruna A, Huber M. Heterogeneity in the differentiation and function of CD8⁺ T cells. Arch Immunol Ther Exp (Warsz). 2014;62(6):449−58. https://doi.org/10.1007/s00005-014-0293-y

  4. Philip M, Schietinger A. CD8⁺ T cell differentiation and dysfunction in cancer. Nat Rev Immunol. 2022;22(4):209−23. https://doi.org/10.1038/s41577-021-00574-3

  5. da Silva DB, Nagashima YG, de Sousa Dantas JCA, dos Santos Tinôco L, Serquiz AC. Lymphocytes count and its correlation with nutritional status in patients with head-and-neck cancer assisted in an oncology hospital in Rio Grande Do Norte. Clin J Nutr Diet 2020;3(1):1−6.

  6. Zhao J, Huang W, Wu Y, Luo Y, Wu B, Cheng J, et al. Prognostic role of pretreatment blood lymphocyte count in patients with solid tumors: a systematic review and meta-analysis. Cancer Cell Int. 2020;20:15. https://doi.org/10.1186/s12935-020-1094-5

  7. Howard R, Kanetsky PA, Egan KM. Exploring the prognostic value of the neutrophil-to-lymphocyte ratio in cancer. Sci Rep. 2019;9(19673). https://doi.org/10.1038/s41598-019-56218-z

  8. Perri F, Ionna F, Longo F, Della Vittoria Scarpati G, De Angelis C, Ottaiano A, et al. Immune response against head and neck cancer: biological mechanisms and implication on therapy. Transl Oncol. 2020;13(2):262−74. https://doi.org/10.1016/j.tranon.2019.11.008

  9. Jiang X, Wu J, Wang J, Huang R. Tobacco and oral squamous cell carcinoma: a review of carcinogenic pathways. Tob Induc Dis. 2019;17:29. https://doi.org/10.18332/tid/111652

  10. Caruntu A, Moraru L, Surcel M, Munteanu A, Costache DO, Tanase C, et al. Persistent changes of peripheral blood lymphocyte subsets in patients with oral squamous cell carcinoma. Healthcare (Basel). 2022;10(2):342. https://doi.org/10.3390/healthcare10020342

  11. Briceño O, Lissina A, Wanke K, Afonso G, von Braun A, Ragon K, et al. Reduced naïve CD8(+) T-cell priming efficacy in elderly adults. Aging Cell. 2016;15(1):14−21. https://doi.org/10.1111/acel.12384

  12. Ziętarska M, Krawczyk-Lipiec J, Kraj L, Zaucha R, Małgorzewicz S. Nutritional status assessment in colorectal cancer patients qualified to systemic treatment. Contemp Oncol (Pozn). 2017;21(2):157−61. https://doi.org/10.5114/wo.2017.68625

  13. Leandro-Merhi VA, Costa CL, Saragiotto L, Aquino JL. Nutritional indicators of malnutrition in hospitalized patients. Arq Gastroenterol. 2019;56(4):447−50. https://doi.org/10.1590/s0004-2803.201900000-74

  14. Rapoport BL, Cooksley T, Johnson DB, Anderson R, Shannon VR. Treatment of infections in cancer patients: an update from the neutropenia, infection and myelosuppression study group of the Multinational Association for Supportive Care in Cancer (MASCC). Expert Rev Clin Pharmacol. 2021;14(3):295−313. https://doi.org/10.1080/17512433.2021.1884067

Published
2024-07-24
How to Cite
1.
Cahyanur R, Widhani A, Pantoro NI, Madadika AT. Association between immune system parameter and clinical characteristics among patients with solid cancer. Med J Indones [Internet]. 2024Jul.24 [cited 2024Jul.27];33(2):93-7. Available from: https://mji.ui.ac.id/journal/index.php/mji/article/view/7272
Issue
Vol. 33 No. 2 (2024): June
Section
Clinical Research

Copyright (c) 2024 Rahmat Cahyanur, Alvina Widhani, Nico Iswanto Pantoro, Annisa Tsana Madadika

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors who publish with Medical Journal of Indonesia agree to the following terms:

  1. Authors retain copyright and grant Medical Journal of Indonesia right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial License that allows others to remix, adapt, build upon the work non-commercially with an acknowledgment of the work’s authorship and initial publication in Medical Journal of Indonesia.
  2. Authors are permitted to copy and redistribute the journal's published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in Medical Journal of Indonesia.